Active	Status	Sponsor type	Region	Phase	Filter
2 Active 1 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
xu, congjian
NCT05620355: Efficacy and Safety of BG2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids.	Recruiting	3	312	RoW	BG2109, Placebo for BG2109, Placebo for add-back therapy, Add-back therapy	Bio Genuine (Shanghai) Biotech Co., Ltd.	Uterine Fibroids, Heavy Menstrual Bleeding	05/24	03/25
NCT05894135: Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis	Recruiting	3	540	RoW	BG2109 100mg, BG2109 200mg, ABT(E2 1 mg / NETA 0.5 mg), BG2109 100mg Placebo, BG2109 200mg Placebo, ABT Placebo	Bio Genuine (Shanghai) Biotech Co., Ltd.	Endometriosis, Moderate to Severe Endometriosis-associated Pain	06/24	03/25